Cephalon reported results from a late-stage trial showing that Nuvigil, which treats sleep disorders, minimized sleepiness in people who had jet lag after traveling from the U.S. to France. Cephalon plans to use the findings to expand the FDA-approved indications of Nuvigil, which is set to enter the U.S. market in the third quarter.

Full Story:

Related Summaries